"Patience is a Super Power" - "The Money is in the waiting"

Friday, March 14, 2025

Silver is often overlooked as an investment and a safe haven. Pan American Silver (PAAS) is a world leader in silver production!

 


As of March 14, 2025, Pan American Silver Corp. (NASDAQ: PAAS) has reported robust financial and operational performance for the fiscal year ending December 31, 2024. Below is a comprehensive overview of the company's financials, production metrics, and asset portfolio.​

Financial Performance

  • Revenue: The company achieved record revenues totaling $2.8 billion for the full year 2024.Stock Titan+1tipranks.com+1

  • Net Earnings: Net earnings for FY 2024 were reported at $112.7 million, translating to basic earnings per share of $0.31.tipranks.com+2Stock Titan+2Investing News+2

  • Cash Flow: Pan American Silver generated record cash flow from operating activities amounting to $724.1 million in 2024.Investing News

Cash and Cash Equivalents

Operating Costs

Production in 2024

Mine Production Details

As of March 14, 2025, Pan American Silver Corp. operates the following mines across the Americas:

Mexico:

Peru:

  • Huarón Mine: Located in the Pasco Region, this mine is known for its polymetallic deposits, including silver, zinc, lead, and copper.en.wikipedia.org

Bolivia:

  • San Vicente Mine: Situated in the Potosí Department, this mine produces silver, zinc, and lead.en.wikipedia.org

Argentina:

  • Cerro Moro Mine: Located in Santa Cruz, this mine produces both silver and gold.en.wikipedia.org

Brazil:

Chile:

  • El Peñón Mine: Located in the Antofagasta Region, this mine produces both gold and silver.panamericansilver.com

  • Minera Florida Mine: Situated in the Santiago Metropolitan Region, this mine produces gold, silver, and zinc.en.wikipedia.org

Canada:

  • Timmins Mine: Located in Ontario, this is a gold-producing mine.

  • Whitney Mine: Situated in Ontario, this mine is part of the company's gold segment.panamericansilver.com

Peru:

  • Shahuindo Mine: Located in the Cajamarca Region, this mine produces gold and silver.

These operations underscore Pan American Silver's extensive mining activities across the Americas, focusing on the production of silver, gold, zinc, lead, and copper.panamericansilver.com+2panamericansilver.com+2panamericansilver.com+2

Total Assets and Mineral Reserves

  • Total Assets: As of December 31, 2024, Pan American Silver's total assets were valued at approximately $6.5 billion.

  • Mineral Reserves:

    • Proven and Probable Silver Reserves: Approximately 550 million ounces.
    • Proven and Probable Gold Reserves: Approximately 5.8 million ounces.panamericansilver.com

These figures underscore Pan American Silver Corp.'s strong financial health, efficient operational management, and substantial asset base, positioning the company favorably within the precious metals industry.

ED Note:

Bought some shares today!

Wednesday, March 12, 2025

Practical business problem solved proving quantum supremacy says D-Wave Quantum!

             


 D-Wave Quantum Inc. (NYSE: QBTS) announced today that its Advantage2 annealing quantum computer has achieved a significant milestone in quantum computing by outperforming one of the world's most powerful classical supercomputers in solving complex magnetic materials simulation problems. This accomplishment, detailed in the peer-reviewed journal Science, represents the first demonstration of quantum computational supremacy on a practical, real-world problem. ​ft.com+9stocktitan.net+9Benzinga+9

In the study, D-Wave's quantum computer simulated the behavior of magnetic materials—a task that would have taken a classical supercomputer nearly one million years to complete. This breakthrough is particularly significant for fields such as materials discovery, medical imaging, electronics, and superconductors, where understanding the quantum nature of magnetic materials is crucial. ​Barron's+4stocktitan.net+4wsj.com+4Benzinga+4stocktitan.net+4stocktitan.net+4

The Advantage2 system used in this research was fabricated in collaboration with SkyWater Technology, a U.S.-based semiconductor manufacturer. This partnership underscores the importance of domestic manufacturing in advancing global technology leadership. ​Barron's+5businesswire.com+5businesswire.com+5stocktitan.net+3Benzinga+3businesswire.com+3

Following the announcement, D-Wave's stock experienced a notable increase, reflecting investor optimism about the company's technological advancements and their potential applications across various industries. ​investors.com

D-Wave's Quantum Supremacy Claim Sparks Industry Buzz

Tuesday, March 11, 2025

Nvidia's interest and investment in Recursion Pharmaceuticals (RXRX) in 2025 could be a game changer for this small-cap!

 

 


Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical-stage biotechnology company that integrates advanced technologies across biology, chemistry, automation, data science, and engineering to decode complex biological systems. Here's an updated overview of the company's financials, partnerships, technological advancements, product pipeline, and other pertinent information:

Financial Overview

  • Cash Position: As of December 31, 2024, Recursion reported cash, cash equivalents, and restricted cash totaling $603.0 million, up from $401.4 million on the same date in 2023.ir.recursion.com

  • Revenue: The company achieved total revenue of $83 million for the fiscal year 2024, reflecting a strong financial performance.tipranks.com

  • Research and Development Expenses: R&D expenses were $74.6 million for Q3 2024, up from $70.0 million in Q3 2023, indicating continued investment in platform expansion and upgrades.globenewswire.com

  • Net Loss: The net loss for Q3 2024 was $95.8 million, compared to $93.0 million in Q3 2023, reflecting ongoing investments in research and development.globenewswire.com

Strategic Partnerships

  • NVIDIA: In July 2023, NVIDIA invested $50 million in Recursion to accelerate the development of AI foundation models for biology and chemistry. This collaboration leverages Recursion's extensive proprietary dataset and NVIDIA's cloud services, including the DGX™ Cloud and BioNeMo platform, to enhance drug discovery capabilities.en.wikipedia.org

  • Roche and Genentech: In December 2021, Recursion entered into a partnership with Roche and its subsidiary Genentech, potentially worth up to $12 billion, to advance therapies in neuroscience and other areas.en.wikipedia.org

  • Bayer: The company has a strategic collaboration with Bayer focusing on oncology research, building upon a previous partnership targeting fibrotic diseases.en.wikipedia.org

  • Exscientia Acquisition: In August 2024, Recursion acquired UK-based biotechnology company Exscientia for $688 million, adding a technology-enabled clinical pipeline and precision chemistry capabilities.globenewswire.com+1en.wikipedia.org+1

Technological Infrastructure

  • Recursion OS: The company's proprietary operating system integrates wet-lab and dry-lab biology experiments, enabling the generation of massive datasets to map and navigate complex biological relationships.sec.gov

  • BioHive-2 Supercomputer: In May 2024, Recursion completed BioHive-2, an NVIDIA-powered AI supercomputer comprising 63 DGX H100 systems with a total of 504 NVIDIA H100 Tensor Core GPUs. Ranked #35 in the TOP500 list of the world's most powerful supercomputers, BioHive-2 significantly enhances Recursion's computational capabilities, facilitating more efficient training of large-scale AI models.

Product Pipeline and Clinical Developments

  • REC-994: This experimental drug targets cerebral cavernous malformation (CCM), a rare brain-related condition. In a mid-stage study reported in September 2024, REC-994 demonstrated safety and tolerability. MRI-based data indicated that the highest dose reduced the number of lesions. However, improvements reported by patients or doctors were not observed at the end of the 12-month treatment period. Recursion plans to meet with the U.S. Food and Drug Administration to discuss further clinical studies.Reuters

  • Clinical Trial Outlook: Recursion anticipates seven clinical trial readouts over the next 18 months for its programs and approximately ten readouts collectively over the same period, including those from the Exscientia acquisition.globenewswire.com+1en.wikipedia.org+1

Intellectual Property

  • Patent Portfolio: As of February 2025, Recursion holds a total of 149 patents globally, with 58 granted. Notably, over 78% of these patents remain active. The majority are filed in the United States, followed by Europe and Canada.

Conclusion

Recursion Pharmaceuticals continues to leverage its robust financial position, strategic partnerships, and advanced technological infrastructure to pioneer AI-driven drug discovery and development. The company's expanding patent portfolio and active clinical pipeline underscore its commitment to transforming the pharmaceutical industry through innovative approaches to complex diseases.

Nvidia-backed Recursion's shares fall on mixed data for rare disorder drug
FaviconReuters

Monday, March 10, 2025

Is it time for Intel? Trading below it's moving averages, a cautious approach is probably in order.


 Intel Corporation (NASDAQ: INTC) is a leading multinational technology company renowned for designing and manufacturing microprocessors, chipsets, and various semiconductor components. Founded in 1968 and headquartered in Santa Clara, California, Intel has played a pivotal role in shaping the modern computing landscape.

Current Business Overview

Intel operates through several key segments:en.wikipedia.org

  • Client Computing Group (CCG): Focuses on personal computing products, including processors and chipsets for PCs and mobile devices.

  • Data Center Group (DCG): Provides server technologies and solutions for enterprise and cloud service providers.

  • Internet of Things Group (IoT): Delivers solutions for connecting devices across various industries.

  • Programmable Solutions Group (PSG): Offers programmable semiconductors, primarily Field-Programmable Gate Arrays (FPGAs).en.wikipedia.org

Financial Performance

Intel's recent financial performance has faced challenges:en.wikipedia.org+14apnews.com+14thetimes.co.uk+14

  • 2024 Financial Results: The company reported a revenue of $53.1 billion, a decrease from previous years, and a net loss of $19.2 billion.en.wikipedia.org

  • Cash Flow: In the fourth quarter of 2024, Intel generated $3.2 billion in cash from operations.intc.com

Strategic Initiatives and Future Focus

Intel has embarked on several strategic initiatives to regain its competitive edge:

  • Intel Foundry Services (IFS): Launched under the "IDM 2.0" strategy, IFS aims to offer manufacturing services to external clients. Notably, Nvidia and Broadcom are testing Intel's 18A process for their chip designs, potentially leading to significant contracts.welt.de+6barrons.com+6finance.yahoo.com+6

  • Manufacturing Expansion: Intel is investing in new fabrication plants (fabs) to enhance production capabilities:axios.com

    • Ohio Facility: Announced a $20 billion investment in a semiconductor factory in Licking County, Ohio. However, the timeline has been adjusted, with production facilities now expected to be completed in 2030 and 2031.axios.com+1marketwatch.com+1

    • Germany Facility: Plans for a €17 billion investment in Magdeburg, Germany, have been postponed, with production now slated for 2027.welt.de+2en.wikipedia.org+2de.wikipedia.org+2

    • Ireland Facility: Intel opened Fab 34 in Leixlip, Ireland, with a €17 billion investment, marking a significant expansion of its manufacturing footprint in Europe.en.wikipedia.org+1en.wikipedia.org+1

Recent Developments

  • Leadership Changes: In December 2024, CEO Pat Gelsinger retired amid financial challenges. David Zinsner and Michelle Johnston Holthaus were appointed interim co-CEOs as the company searches for a permanent leader.en.wikipedia.org+2apnews.com+2nypost.com+2

  • CHIPS and Science Act: Intel secured $8.5 billion in federal grants to build new fabs in Arizona and Ohio and to upgrade existing plants in Oregon and New Mexico, aligning with efforts to bolster domestic semiconductor manufacturing.en.wikipedia.org+1investors.com+1

Investment Considerations

Investors should weigh the following factors:

  • Competitive Landscape: Intel faces stiff competition from companies like TSMC and Nvidia. Its ability to attract clients like Nvidia and Broadcom to its foundry services could signal a positive shift.thetimes.co.uk+1barrons.com+1

  • Financial Health: The recent net loss and leadership changes highlight challenges. However, strategic investments and potential new contracts may pave the way for recovery.en.wikipedia.org+2apnews.com+2thetimes.co.uk+2

  • Manufacturing Expansion: Intel's substantial investments in new fabs demonstrate a commitment to enhancing production capabilities, though delays in some projects warrant attention.

In conclusion, while Intel faces challenges, its strategic initiatives and investments position it to potentially regain its competitive stature in the semiconductor industry.

​Intel Corp. (INTC)

$20.44
-$37.96(-65.00%)Past 5 years

As of March 10, 2025, Intel Corporation (NASDAQ: INTC) is trading at $20.44. Technical analysis indicates a predominantly bearish outlook:kavout.com
  • Moving Averages: The stock is trading below key moving averages, including the 50-day ($21.22) and 200-day ($24.15) simple moving averages, signaling potential downward momentum.barchart.com

  • Relative Strength Index (RSI): An RSI of 40.52% suggests the stock is nearing oversold conditions, which could precede a rebound.barchart.com

  • Trend Analysis: INTC is exhibiting weak performance within a declining trend channel over the medium to long term, indicating increasing pessimism among investors and a potential for further decline.investtech.com

Recent developments include reports that Nvidia and Broadcom are testing Intel's 18A manufacturing process for advanced AI-chip production, which could lead to significant manufacturing deals for Intel.markets.businessinsider.com

Given the current technical indicators and market conditions, it may be prudent to exercise caution and await more favorable signals before considering an investment in Intel's stock.

Intel's Strategic Moves Amidst Industry Challenges